Bausch Health Companies Inc.

Bausch Health Companies Inc. is a global, diversified specialty pharmaceutical and medical device company. It develops, manufactures, and markets a broad range of branded, generic, and branded generic pharmaceuticals, over-the-counter (OTC) products, and aesthetic medical devices. These are primarily in the therapeutic areas of gastroenterology (GI), hepatology, neurology, and dermatology. Through its approximately 88% ownership of Bausch + Lomb Corporation, the company also offers branded and branded generic pharmaceuticals, OTC products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment) in eye health. The company's products are marketed directly or indirectly in approximately 90 countries. Bausch Health operates through five reportable segments. The Salix segment focuses on U.S. sales of GI products, with the Xifaxan® product line representing approximately 85% of its revenues. The International segment handles sales outside the U.S. of branded pharmaceutical products, branded generic pharmaceutical products, and OTC products, excluding Bausch + Lomb products and Solta Medical aesthetic medical devices. The Solta Medical segment covers global sales of Solta Medical aesthetic medical devices. The Diversified segment includes U.S. sales of pharmaceutical products in neurology and other therapeutic classes, dermatology products, generic pharmaceutical products, and dentistry products. Finally, the Bausch + Lomb segment encompasses global sales of Bausch + Lomb Vision Care, Surgical, and Pharmaceuticals products.